{
  "author": {
    "name": "Philip Cyr Sr",
    "webUrl": "/author/profile/philip-cyr-sr/",
    "description": "",
    "imageLarge": "https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g",
    "estimate": 1,
    "social": [],
    "articles": [
      {
        "uri": "/2022/02/11/a-shared-opportunity-the-future-of-cell-and-gene-therapy/",
        "title": "A shared opportunity: The future of cell and gene therapy",
        "byline": "Anshul Mangal and Philip Cyr, Sr.",
        "kicker": "Commentary",
        "prettyDate": "February 11, 2022",
        "timeToRead": "7 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2018/11/GeneEditing.jpg",
          "width": "616",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/anshul-mangal/",
            "name": "Anshul Mangal"
          },
          {
            "webUrl": "/author/profile/philip-cyr-sr/",
            "name": "Philip Cyr, Sr."
          }
        ],
        "kickerNode": [
          {
            "uri": "/commentary/",
            "sectionName": "Commentary"
          }
        ],
        "summary": "The commercialization of cell and gene therapies raises several complex conversations and questions for employers and payers.",
        "body": null
      }
    ]
  }
}